A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : TATI / tumor-associated trypsin inhibitor

[Related PubMed/MEDLINE]
Total Number of Papers: 123
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   TATI  (>> Co-occurring Abbreviation)
Long Form:   tumor-associated trypsin inhibitor
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 TATI, TAT-2, and CRP as Prognostic Factors in Colorectal Cancer. CI, CRP, TAT-2
2021 Tumor-Associated Trypsin Inhibitor (TATI) as a Biomarker of Poor Prognosis in Oropharyngeal Squamous Cell Carcinoma Irrespective of HPV Status. DSS, HPV, HUS, OS, S-TATIs
2020 Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers. ERCC1, FGFR3, TP53
2020 Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma. CKD grade, CSS, RCC
2020 Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer. CI, CRP, IQR, TAT-2
2019 Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy. OS, PFS
2018 Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men. AA, ANX2, HSP60, PCa, SPINK1, TRUS, WHO
2018 Postoperative CEA is a better prognostic marker than CA19-9, hCGbeta or TATI after resection of colorectal liver metastases. CA19-9, CEA, hCG-beta
2016 Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI. CEA, ROC
10  2015 Biomarker development, from bench to bedside. hCG, PSA, SPINK1, TAT
11  2015 Claudin-5 is associated with elevated TATI and CA125 levels in mucinous ovarian borderline tumors. CA, TJ
12  2015 Emerging Roles of SPINK1 in Cancer. PSTI, SPINK
13  2015 Tumor-associated trypsin inhibitor in patients with endometrial cancer. ---
14  2014 Assessment of the tumor-associated trypsin inhibitor (TATI) marker in patients with carcinoma of the uterine body 17 years after treatment. ---
15  2014 Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma: potential implications for viral hepatocarcinogenesis. ESTs, HCC, HCV, MMPs, RT-PCR, SPINK1, TIMPs
16  2014 TATI as a biomarker. PSTI
17  2013 A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells. GS, PCa
18  2013 A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diagnosis of metastasis in patients with breast cancer. sEGFR, TATI-MBCS
19  2013 Pancreatic secretory trypsin inhibitor causes autocrine-mediated migration and invasion in bladder cancer and phosphorylates the EGF receptor, Akt2 and Akt3, and ERK1 and ERK2. PSTI
20  2013 Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-beta (hCGbeta) in patients with hepatocellular carcinoma. HCC, hCG-beta, IFMA
21  2013 The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer. ELISA
22  2012 Creatinine clearance, cystatin C, beta2-microglobulin and TATI as markers of renal function in patients with proteinuria. B2M, CrCl, CYST, ESRD, GFR
23  2012 Validation and comparison of tumor-associated trypsin inhibitor (TATI) immunoassays. RIA
24  2011 Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder. UCB
25  2011 Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients. OS, RT
26  2011 Roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases. EGF, SPINK1
27  2010 Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. CRC, DFS, OS, s-TATI, t-TATI
28  2009 High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. CEA, IHC, TMAs
29  2008 Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells. CM-5M21
30  2008 Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer. AUC, CI, HR, pT, SPF
31  2008 Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma. UBC
32  2008 Urinary matrix metalloproteinase -8, -9, -14 and their regulators (TRY-1, TRY-2, TATI) in patients with diabetic nephropathy. DNP, MMP-9, PMN, TRY
33  2007 Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. CgA, PSA
34  2007 Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. ETR, HCC, PV
35  2006 Effects of cigarette smoking on serum fluoride concentrations and renal function integrity after 1 MAC-h sevoflurane anaesthesia. ---
36  2005 Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics. CEA, US
37  2005 Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. ---
38  2005 High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. ---
39  2005 Preoperative serum hCGbeta as a prognostic marker in primary fallopian tube carcinoma. PFTC
40  2005 Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. NMP22, ROC, TCC
41  2004 Assessment of tumor-associated trypsin inhibitor (TATI) as a marker of renal function. Cr, GFR, LMW
42  2004 Cyst fluid tumor-associated trypsin inhibitor may be helpful in the differentiation of cystic pancreatic lesions. CEA, CPN, EC, MCA, SCA
43  2004 Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. ---
44  2003 Co-expression of trypsin and tumour-associated trypsin inhibitor (TATI) in colorectal adenocarcinomas. RT-PCR
45  2003 Fluoride metabolism in smokers and non-smokers following enflurane anaesthesia. CI, MAC
46  2003 Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor. ---
47  2003 Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. ---
48  2003 Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. MSPs
49  2003 Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies. CEA, CRP
50  2002 MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells. MMPs, TAT-2
51  2002 Tumor-associated trypsin inhibitor. ---
52  2001 Association of trypsin-2 with activation of gelatinase B and collagenase-2 in human bronchoalveolar lavage fluid in vivo. BALF, MMPs, PI
53  2001 Preoperative serum concentration of hCGbeta as a prognostic factor in ovarian cancer. ---
54  2001 Relationship between renal function and blood level of chromogranin A. CgA, GFR
55  2001 Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer. TPA
56  2001 The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. MMPs
57  2001 Trypsinogen-1, -2 and tumour-associated trypsin-inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas. ---
58  2000 Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. CMTs, DOXY, MMP
59  2000 Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia. GFR, SCC, TPA, TPS
60  1999 Elevated serum inhibin and tumor-associated trypsin inhibitor concentrations in a young woman with dysgerminoma of the ovary. ---
61  1999 TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer. CA125
62  1999 Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. PSTI, RCC, RT-PCR
63  1998 Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in Stage III epithelial ovarian cancer. ---
64  1998 Serum levels of tumor associated trypsin inhibitor (TATI) and glomerular filtration rate. beta2m, GFR
65  1998 Tumor-associated trypsin inhibitor (TATI) and renal function. GFR
66  1997 Serum levels of the tumour-associated trypsin inhibitor in patients with endometriosis. ---
67  1996 Serum tumour-associated trypsin inhibitor (TATI) and renal function. beta2m, GFR, MW
68  1996 TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder. AFP, beta-hCG, CEA, PSA, SCC, TPA
69  1995 Markers supplementing CA 125 in ovarian cancer. AFP
70  1995 TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer. ---
71  1995 Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer. CA125
72  1995 Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242. ---
73  1995 Tumour-associated trypsin inhibitor and renal cell carcinoma. RCC
74  1994 Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer. ---
75  1994 Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma. CEA
76  1993 Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids. CEA
77  1993 Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. IFMA, RIA, SAB, SAB-IFMA
78  1993 Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening. CEA, NSE
79  1993 Squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), and tumour-associated trypsin inhibitor (TATI) for monitoring head and neck cancer. CEA, SCC
80  1993 [Clinical evaluation of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological tumor]. ---
81  1992 Chemotherapy as initial treatment for cervical carcinoma: clinical and tumor marker response. CEA, SCC
82  1992 Squamous cell carcinoma antigen, tumor associated trypsin inhibitor and tissue polypeptide specific antigen in follow up of stage III cervical cancer. SCC, TPS
83  1992 [Renal cell cancer in childhood]. ---
84  1992 [Significance of the the tumor markers, Ca-125 and tumor-associated trypsin inhibitor in patients with carcinoma of the cervix and uterus]. ---
85  1991 Biology and function of tumor-associated trypsin inhibitor, TATI. PSTI
86  1991 Clinical evaluation of tumor-associated trypsin inhibitor (TATI). Proceedings of a symposium. Barcelona, September 24, 1989. ---
87  1991 Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer. ---
88  1991 Evaluation of TATI and other markers in solid tumors. ---
89  1991 Evaluation of tumor-associated trypsin inhibitor (TATI) in women with benign and malignant gynecological disease. ---
90  1991 Human colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor-associated trypsinogen. TAT-I
91  1991 Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases. ---
92  1991 Serum TATI levels and clinical correlation in tumors of the head and neck. ENT, RIA
93  1991 Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease. ---
94  1991 Tumor-associated trypsin inhibitor (TATI) in bone diseases. ---
95  1991 Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA. CEA
96  1991 Tumor-associated trypsin inhibitor (TATI) in pleural effusions. ---
97  1991 Tumor-associated trypsin inhibitor (TATI) in primary esophageal carcinoma. ---
98  1991 Tumor-associated trypsin inhibitor (TATI) in the diagnosis of lung cancer. ---
99  1991 Tumor-associated trypsin inhibitor as a possible marker in male infertility. ---
100  1991 Tumor-associated trypsin inhibitor in induced and acquired immunodeficiency. Studies on transplanted and HIV-infected patients. ---